Treatment Progress for Desmoid Sarcoma
A new small molecule is in development for desmoid tumours. The molecule known as AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI).
Ayala Pharmaceuticals who are developing the molecule, reported that they have completed patient enrolment for Part A of their Phase 2/3 RINGSIDE clinical trial. A phase 2/3 trial is one that looks to determine the best dose based on efficacy and safety. Following the results of part A, a dose will be selected to take forward in a larger trial measuring progression free survival in desmoid sarcoma patients.
ANZSA is very proud to have collaborated to ensure this potential new treatment for a rare and aggressive form of sarcoma comes to fruition.
While desmoid tumours are not malignant, i.e. they do not spread to other parts of the body they can be very aggressive and grow into other organs close by. For this reason treatments are needed to help control and eliminate the tumours.